Prevalence and associations of metabolic syndrome in patients with alcohol use disorder.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 02 2022
16 02 2022
Historique:
received:
24
07
2021
accepted:
14
01
2022
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Excessive alcohol consumption has been associated with different components of the metabolic syndrome (MetS) such as arterial hypertension, dyslipidemia, type 2 diabetes or obesity. We aimed to analyze the prevalence and associations of MetS in patients with Alcohol Use Disorder (AUD). Cross-sectional study in heavy drinkers admitted for the treatment of AUD between 2013 and 2017. Medical comorbidity, anthropometric data, alcohol use and biological parameters were obtained. MetS was established according to the harmonized definition. A total of 728 patients (22% women) were included; median age was 47 years (IQR: 40-53.5), median alcohol consumption was 160 g/day (IQR: 115-240) and prevalence of MetS was 13.9%. The multivariate analysis showed a significant dose-response effect of estimated glomerular filtration (eGFR) and MetS: relative to patients with eGFR > 90 mL/min, those with eGFR (60-90 mL/min) and those with eGFR < 60 mL/min were 1.93 times (95% CI 1.18-3.15) and 5.61 times (95% CI 1.66-19.0) more likely to have MetS, respectively. MetS was significantly associated with hyperuricemia (OR 2.28, 95% CI 1.36-3.82) and elevated serum GGT (OR 3.67, 95% CI 1.80-7.46). Furthermore, for every increase of 1 year in age, the probability of MetS increased significantly (OR 1.03, 95% CI 1.01-1.05). MetS in heavy drinkers is independently associated with reduced kidney function and metabolic risk factors including hyperuricemia and elevated serum GGT.
Identifiants
pubmed: 35173187
doi: 10.1038/s41598-022-06010-3
pii: 10.1038/s41598-022-06010-3
pmc: PMC8850419
doi:
Substances chimiques
gamma-Glutamyltransferase
EC 2.3.2.2
gamma-glutamyltransferase, human
EC 2.3.2.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2625Informations de copyright
© 2022. The Author(s).
Références
Rochlani, Y., Pothineni, N. V., Kovelamudi, S. & Mehta, J. L. Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds. Ther. Adv. Cardiovasc. Dis. 11, 215–225 (2017).
pubmed: 28639538
pmcid: 5933580
doi: 10.1177/1753944717711379
Justice, A. C. et al. Predictive accuracy of the veterans aging cohort study index for mortality with HIV infection. JAIDS J. Acquir. Immune Defic. Syndr. 62, 149–163 (2013).
pubmed: 23187941
doi: 10.1097/QAI.0b013e31827df36c
Scuteri, A. et al. Metabolic syndrome across Europe: Different clusters of risk factors. Eur. J. Prev. Cardiol. 22, 486–491 (2015).
pubmed: 24647805
doi: 10.1177/2047487314525529
Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998).
pubmed: 9686693
doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
Einhorn, D. et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237–252 (2003).
pubmed: 12924350
doi: 10.4158/EP.9.S2.5
Alberti, K. G. M. M., Zimmet, P. & Shaw, J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet. Med. 23, 469–480 (2006).
pubmed: 16681555
doi: 10.1111/j.1464-5491.2006.01858.x
Grundy, S. M. et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735–2752 (2005).
pubmed: 16157765
doi: 10.1161/CIRCULATIONAHA.105.169404
Alberti, K. G. M. M. et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International. Circulation 120, 1640–1645 (2009).
pubmed: 19805654
doi: 10.1161/CIRCULATIONAHA.109.192644
Ference, B. A., Kastelein, J. J. P. & Catapano, A. L. Lipids and Lipoproteins in 2020. JAMA J. Am. Med. Assoc. 324, 595–596 (2020).
doi: 10.1001/jama.2020.5685
Simmons, R. K. et al. The metabolic syndrome: Useful concept or clinical tool? Report of a WHO expert consultation. Diabetologia 53, 600–605 (2010).
pubmed: 20012011
doi: 10.1007/s00125-009-1620-4
Tauler, P. et al. Prevalence of premorbid metabolic syndrome in Spanish adult workers using IDF and ATPIII diagnostic criteria: Relationship with cardiovascular risk factors. PLoS One 9, e89281 (2014).
pubmed: 24586656
pmcid: 3930690
doi: 10.1371/journal.pone.0089281
Observatorio Español de las Drogas las Adicciones Delegación del Gobierno para el Plan Nacional sobre Drogas. Monografía. Alcohol 2021: Consumo y consecuencias. (2021). https://pnsd.sanidad.gob.es/profesionales/publicaciones/catalogo/catalogoPNSD/publicaciones/pdf/2021_Monografia_Alcohol_consumos_y_consecuencias.pdf
Vancampfort, D. et al. The prevalence of metabolic syndrome in alcohol use disorders: A systematic review and meta-analysis. Alcohol Alcohol. 51, 515–521 (2016).
pubmed: 27337988
doi: 10.1093/alcalc/agw040
Jarvis, C. M. et al. Cardiovascular risk factors and metabolic syndrome in alcohol- and nicotine-dependent men and women. J. Cardiovasc. Nurs. 22, 429–435 (2007).
pubmed: 18090180
doi: 10.1097/01.JCN.0000297387.21626.88
Hernández-Rubio, A. et al. Association of hyperuricemia and gamma glutamyl transferase as a marker of metabolic risk in alcohol use disorder. Sci. Rep. 10, 20060 (2020).
pubmed: 33208850
pmcid: 7674473
doi: 10.1038/s41598-020-77013-1
Abdul-Rahman, A. K., Card, T. R., Grainge, M. J. & Fleming, K. M. All-cause and cause-specific mortality rates of patients treated for alcohol use disorders: A meta-analysis. Subst. Abus. 39, 509–517 (2018).
pubmed: 29958085
doi: 10.1080/08897077.2018.1475318
Kim, S.-J. & Kim, D.-J. Alcoholism and diabetes mellitus. Diabetes Metab. J. 36, 108–115 (2012).
pubmed: 22540046
pmcid: 3335891
doi: 10.4093/dmj.2012.36.2.108
Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009).
pubmed: 19414839
pmcid: 2763564
doi: 10.7326/0003-4819-150-9-200905050-00006
Ryan, M. C., Fenster Farin, H. M., Abbasi, F. & Reaven, G. M. Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease. Am. J. Cardiol. 102, 40–46 (2008).
pubmed: 18572033
doi: 10.1016/j.amjcard.2008.02.096
Jayedi, A., Soltani, S., Zargar, M. S., Khan, T. A. & Shab-Bidar, S. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ 370, m3324 (2020).
pubmed: 32967840
pmcid: 7509947
doi: 10.1136/bmj.m3324
Guallar-Castillón, P. et al. Magnitude and management of metabolic syndrome in Spain in 2008–2010: The ENRICA Study. Rev. Española Cardiol. (English Ed.) 67, 367–373 (2014).
doi: 10.1016/j.recesp.2013.08.014
Kassi, E., Pervanidou, P., Kaltsas, G. & Chrousos, G. Metabolic syndrome: Definitions and controversies. BMC Med. 9, 48 (2011).
pubmed: 21542944
pmcid: 3115896
doi: 10.1186/1741-7015-9-48
Zhang, X. & Lerman, L. O. The metabolic syndrome and chronic kidney disease. Transl. Res. 183, 14–25 (2017).
pubmed: 28025032
doi: 10.1016/j.trsl.2016.12.004
Garofalo, C. et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 91, 1224–1235 (2017).
pubmed: 28187985
doi: 10.1016/j.kint.2016.12.013
Yamagata, K. et al. Effect of behavior modification on outcome in early- To moderate-stage chronic kidney disease: A cluster-randomized trial. PLoS One 11, e0151422 (2016).
pubmed: 26999730
pmcid: 4801411
doi: 10.1371/journal.pone.0151422
Câmara, N. O. S., Iseki, K., Kramer, H., Liu, Z. H. & Sharma, K. Kidney disease and obesity: Epidemiology, mechanisms and treatment. Nat. Rev. Nephrol. 13, 181–190 (2017).
pubmed: 28090083
doi: 10.1038/nrneph.2016.191
Park, S. et al. Reduced risk for chronic kidney disease after recovery from metabolic syndrome: A nationwide population-based study. Kidney Res. Clin. Pract. 39, 180–191 (2020).
pubmed: 32344501
pmcid: 7321670
doi: 10.23876/j.krcp.20.016
Choi, J. I. et al. The association between obesity phenotypes and early renal function decline in adults without hypertension, dyslipidemia, and diabetes. Korean J. Fam. Med. 40, 176–181 (2019).
pubmed: 31072076
pmcid: 6536908
doi: 10.4082/kjfm.18.0139
Wu, Z. et al. Metabolic syndrome is associated with rapid estimated glomerular filtration rate decline in a Chinese community-based population. Diabetes Metab. Syndr. Obes. Targets Ther. 12, 2085–2093 (2019).
doi: 10.2147/DMSO.S217326
Kawamoto, R., Akase, T., Ninomiya, D., Kumagi, T. & Kikuchi, A. Metabolic syndrome is a predictor of decreased renal function among community-dwelling middle-aged and elderly Japanese. Int. Urol. Nephrol. 51, 2285–2294 (2019).
pubmed: 31642000
doi: 10.1007/s11255-019-02320-0
Lee, D. S. et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: The Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 27, 127–133 (2007).
pubmed: 17095717
doi: 10.1161/01.ATV.0000251993.20372.40
Voruganti, V. S. et al. Genetic influence on variation in serum uric acid in American Indians: The strong heart family study. Hum. Genet. 126, 667–676 (2009).
pubmed: 19590895
pmcid: 2784272
doi: 10.1007/s00439-009-0716-8
Kunutsor, S. K., Apekey, T. A. & Seddoh, D. Gamma glutamyltransferase and metabolic syndrome risk: A systematic review and dose–response meta-analysis. Int. J. Clin. Pract. 69, 136–144 (2015).
pubmed: 25363194
doi: 10.1111/ijcp.12507
Bonomini, F., Rodella, L. F. & Rezzani, R. Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis. 6, 109–120 (2015).
pubmed: 25821639
pmcid: 4365955
doi: 10.14336/AD.2014.0305
Bo, S. et al. Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: A possible implication for oxidative stress. World J. Gastroenterol. 11, 7109–7117 (2005).
pubmed: 16437656
pmcid: 4725082
doi: 10.3748/wjg.v11.i45.7109
Koenig, G. & Seneff, S. Gamma-Glutamyltransferase: A predictive biomarker of cellular antioxidant inadequacy and disease risk. Dis. Mark. 2015, 818570 (2015).
Lai, X. et al. Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng–Tongji Cohort. Int. J. Cardiol. 224, 299–304 (2016).
pubmed: 27665401
doi: 10.1016/j.ijcard.2016.09.035
Yadav, D. et al. Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. Atherosclerosis 241, 271–277 (2015).
pubmed: 25957887
doi: 10.1016/j.atherosclerosis.2015.04.797
Li, L. et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 15, 122 (2014).
pubmed: 25064611
pmcid: 4132278
doi: 10.1186/1471-2369-15-122
Razzouk, L. & Muntner, P. Ethnic, gender, and age-related differences in patients with the metabolic syndrome. Curr. Hypertens. Rep. 11, 127–132 (2009).
pubmed: 19278602
doi: 10.1007/s11906-009-0023-8
Jiang, B. et al. Age and gender-specific distribution of metabolic syndrome components in East China: Role of hypertriglyceridemia in the SPECT-China study. Lipids Health Dis. 17, 92 (2018).
pubmed: 29678174
pmcid: 5910574
doi: 10.1186/s12944-018-0747-z
Yamaki, N. et al. Telomere shortening in alcohol dependence: Roles of alcohol and acetaldehyde. J. Psychiatr. Res. 109, 27–32 (2019).
pubmed: 30466069
doi: 10.1016/j.jpsychires.2018.11.007
Wu, H. F. et al. Age, gender, and socioeconomic gradients in metabolic syndrome: biomarker evidence from a large sample in Taiwan, 2005–2013. Ann. Epidemiol. 27, 315-322.e2 (2017).
pubmed: 28595736
doi: 10.1016/j.annepidem.2017.04.003